{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-001852","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.778034+00:00","generated_at":"2026-06-06T20:50:51.949729+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Perspective Therapeutics closes $89.8M combined public offering and Lantheus private placement","bullets":["Gross proceeds: $69.0M from public offering + $20.8M from private placement = $89.8M total.","Public offering: 156.4M shares at $0.37/sh and pre-funded warrants for 30.1M shares at $0.369/sh.","Private placement to Lantheus: 56.3M shares at $0.37/sh for $20.8M gross.","Proceeds to fund R&D, clinical trials, manufacturing, and potential acquisitions.","Underwriters' option for 24.3M additional shares was exercised in full."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-001852","json":"https://secwatch.observer/filing/0001437749-24-001852.json","markdown":"https://secwatch.observer/filing/0001437749-24-001852.md","text":"https://secwatch.observer/filing/0001437749-24-001852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774924001852/0001437749-24-001852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774924001852/isr20240121_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:50:51.949729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1800c0337f31d5f12f8ce17775f4b08b12f6f90b","claim":"Perspective Therapeutics, Inc. entered into Underwriting Agreement with Oppenheimer & Co. Inc., as representative of the underwriters valued at approximately $69.0 million (effective 2024-01-17).","evidence_excerpt":"On January 17, 2024, Perspective Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten public offering (the “Public Offering”) of 132,075,218 shares","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774924001852/0001437749-24-001852-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Oppenheimer & Co. Inc., as representative of the underwriters"},{"label":"Value","value":"approximately $69.0 million"},{"label":"Effective","value":"2024-01-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}